市场调查报告书

皮肤癌:机会评估,流行病学研究,市场动态,及开发平台分析(2020年下半年)

Skin Cancers - Opportunity Assessments, Epidemiology Studies, Market Dynamics, and Pipeline Analytics H2 2020

出版商 GervanoRA Data Services LLP 商品编码 968652
出版日期 内容资讯 英文 343 Pages
订单完成后即时交付
价格
皮肤癌:机会评估,流行病学研究,市场动态,及开发平台分析(2020年下半年) Skin Cancers - Opportunity Assessments, Epidemiology Studies, Market Dynamics, and Pipeline Analytics H2 2020
出版日期: 2020年11月03日内容资讯: 英文 343 Pages
简介

本报告提供皮肤癌的相关调查,皮肤癌及市场概要,市场机会,成长及阻碍因素,进行中的研究开发阶段和各市场区隔的开发平台分析,竞争情形,主要企业的详细的洞察及新兴企业的简介等资讯。

目录

第1章 简介

第2章 摘要整理

  • 报告概要
  • 皮肤癌的竞争空间主要的活动
  • 主要调查结果的报告
    • 成长要素
    • 阻碍因素
    • 市场机会
  • 竞争情形的市场动态
    • 新兴疗法的未满足需求与市场的需求
    • 给药途径的未满足需求与市场的需求
    • 各地区的未满足需求与市场的需求

第3章 开发平台分析预测

  • 开发平台分析比较概述
    • 各开发阶段
    • 各地区
    • 各给药途径
    • 各分子类型
    • 各医药品分类
    • 各类型企业
    • 各分子标的

第4章 皮肤癌概要

第5章 皮肤癌的市场动态

第6章 皮肤癌开发平台的专利分析

第7章 皮肤癌的开发平台分析

  • 各开发阶段的开发平台分析
    • 前登记
    • 阶段III
    • 阶段II
    • 阶段I/II
    • 阶段I
    • 前临床
    • 初期R&D
    • 非活动和结束的开发平台
  • 各地区
  • 各给药途径
    • 各非口服
    • 各口服及局部
  • 各医药品分类
  • 各作用机制
  • 各分子类型
  • 各目标受体
  • 各皮肤癌类型
  • 各类型企业

第8章 开发平台药物的说明与开发里程碑

第9章 临床试验概要

第10章 开发平台估计核准计划

第11章 各竞争基准机会评估

第12章 现在及未来的竞争情形

  • 新兴企业的简介
目录

GervanoRA's pipeline analysis and opportunity assessment report "Skin Cancers - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H2 2020" analyzed and assessed Skin Cancer pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Skin Cancers drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Skin Cancers area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Skin Cancers drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

Our comprehensive analysis on the Skin Cancers drug pipeline identified 681 drug candidates undergoing different stages of development- from Early R&D stage to Phase 3 stage and Pre-Registration. Among these, a total of 388 drug candidates are in clinical stages of development and 195 molecules are in non-clinical stage of development. The drug pipeline consists of three (03) pipeline molecules in pre-registration, 36 pipeline molecules are in late clinical stage of development (Phase 3), and a total of 163 pipeline molecules in early clinical stage of development (Phase 1). The report also aims to provide analytics and deep insights on the expected market share of the key Phase 3 and Phase 2 pipeline drugs for a better understanding of the Skin Cancers market in the coming years and know the competition which is paramount for any new entrant.

The report has covered more than 575 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)
  • Epidemiological Studies
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 2 and Phase 3) Pipeline Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Plotting of the Anticipated Market Share for the New Entrants (Phase 3 and Phase 2 Drugs)
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE SKIN CANCER COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES
  • 2.4. MARKET DYNAMICS OF SKIN CANCERS COMPETITIVE LANDSCAPE
    • 2.4.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES
    • 2.4.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION
    • 2.4.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

  • 3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS
    • 3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT
    • 3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY
    • 3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION
    • 3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE
    • 3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS
    • 3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE
    • 3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET

CHAPTER 04: SKIN CANCERS OVERVIEW

CHAPTER 05: MARKET DYNAMICS OF SKIN CANCERS COMPETITIVE SPACE

CHAPTER 6: PATENT ANALYTICS OF SKIN CANCERS PIPELINE DRUGS

CHAPTER 07: PIPELINE DRUGS ANALYTICS OF SKIN CANCERS

  • 7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 7.1.1. PRE-REGISTRATION PIPELINE DRUGS
    • 7.1.2. PHASE III PIPELINE DRUGS
    • 7.1.3. PHASE II PIPELINE DRUGS
    • 7.1.4. PHASE I/II PIPELINE DRUGS
    • 7.1.5. PHASE I PIPELINE DRUGS
    • 7.1.6. PRE-CLINICAL PIPELINE DRUGS
    • 7.1.7. EARLY R&D PIPELINE DRUGS
    • 7.1.8. INACTIVE AND TERMINATED PIPELINE DRUGS
  • 7.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 7.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • 7.3.1. PIPELINE ANALYTICS BY PARENTERALS AS ROUTE OF ADMINISTRATION
    • 7.3.2. PIPELINE ANALYTICS BY ORAL AND TOPICAL ROUTE OF ADMINISTRATIONS
  • 7.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
  • 7.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
  • 7.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 7.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
  • 7.8. PIPELINE DRUGS ANALYTICS BY SKIN CANCER TYPE
  • 7.9. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 09: CLINICAL TRIALS SUMMARY

CHAPTER 10: ESTIMATED APPROVAL TIMELINES OF PIPELINE DRUGS

CHAPTER 11: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

CHAPTER 12: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

12.1: EMERGING COMPANIES

    • 12.1.1 EMERGING COMPANY PROFILES